CLINICAL TRIALS PROFILE FOR ADDERALL 12.5
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
505(b)(2) Clinical Trials for Adderall 12.5
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00746733 ↗ | Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC | Completed | Shire | Phase 1 | 2008-09-08 | The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Adderall 12.5
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00069927 ↗ | Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-08-01 | RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help. |
| NCT00069927 ↗ | Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression | Terminated | University of South Florida | Phase 2 | 2003-08-01 | RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help. |
| NCT00247572 ↗ | Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories | Completed | New River Pharmaceuticals | Phase 2 | 2005-09-01 | This research is being done to evaluate if NRP 104 is a safe drug. The other purpose is to learn if NRP104, when injected into a vein, produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss. |
| NCT00248092 ↗ | Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse | Completed | New River Pharmaceuticals | Phase 1/Phase 2 | 2006-01-01 | This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational drug. This means that it has not been approved by the U.S. Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss. |
| NCT00279409 ↗ | Treatment of Children With ADHD Who do Not Fully Respond to Stimulants | Terminated | Bristol-Myers Squibb | Phase 2 | 2006-07-01 | The purpose of this pilot is to initiate a program of research into the development of effective medication techniques to treat those children with ADHD who are referred because they are "partial" or "non-responders" to standard stimulant treatment. |
| NCT00279409 ↗ | Treatment of Children With ADHD Who do Not Fully Respond to Stimulants | Terminated | National Institute of Mental Health (NIMH) | Phase 2 | 2006-07-01 | The purpose of this pilot is to initiate a program of research into the development of effective medication techniques to treat those children with ADHD who are referred because they are "partial" or "non-responders" to standard stimulant treatment. |
| NCT00279409 ↗ | Treatment of Children With ADHD Who do Not Fully Respond to Stimulants | Terminated | Otsuka Pharmaceutical Co., Ltd. | Phase 2 | 2006-07-01 | The purpose of this pilot is to initiate a program of research into the development of effective medication techniques to treat those children with ADHD who are referred because they are "partial" or "non-responders" to standard stimulant treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Adderall 12.5
Condition Name
Clinical Trial Locations for Adderall 12.5
Trials by Country
Clinical Trial Progress for Adderall 12.5
Clinical Trial Phase
Clinical Trial Sponsors for Adderall 12.5
Sponsor Name
